Dr Heather J Landau, MD is an Associate Attending Physician on the Adult Bone Marrow Transplant, Cellular Therapy and Multiple Myeloma services at Memorial Sloan Kettering (MSK) Cancer Center, New York, US and is the Director of the Amyloid Program. She is also an Associate Professor of Clinical Medicine at Weill Cornell Medical College. She received her MD from Upstate Medical University and after an Internal Medicine Residency at the University of Colorado, she pursued her Hematology and Oncology Fellowship at MSK where she remains on faculty. Her career has focused on improving outcomes for patients with plasma cell disorders including both Multiple Myeloma (MM) and Light Chain (AL) Amyloidosis.
Dr Landau has led several investigator-initiated trials focused on increasing access to novel, effective therapies and has developed innovative ways to deliver high-dose therapy and stem cell transplant. Translational efforts have focused on genomic and immune profiling of pathologic plasma cells in MM and AL amyloidosis and developing a novel blood-based technique to track minimal residual disease. She is currently a co-chair for the Center for International Blood & Marrow Transplant Research (CIBMTR) Working Committee for Plasma Cell Disorders, member of the International Kidney Monoclonal Gammopathy consortium where she leads the Renal Transplantation Working Group. She is the recipient of an American Society of Hematology Bridge Grant for her work on minimal residual disease and along with Dr Liu is a co-PI on J&J’s Improving Detection of AL Amyloidosis QuickFire Challenge Grant.
